Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura

Citation
R. Watanabe et al., Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura, CL APPL T-H, 7(3), 2001, pp. 229-233
Citations number
25
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Hematology
Journal title
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
ISSN journal
1076-0296 → ACNP
Volume
7
Issue
3
Year of publication
2001
Pages
229 - 233
Database
ISI
SICI code
1076-0296(200107)7:3<229:PLOTPA>2.0.ZU;2-5
Abstract
In this study, we examined changes in the plasma levels of total plasminoge n activator inhibitor-I (PAI-I) and tissue-type plasminogen activator (tPA) /PAI-I complex in patients with disseminated intravascular coagulation (DIC ) and in those with thrombotic thrombocytopenic purpura (TTP) to investigat e the fibrinolytic function and its relation to organ failure. The plasma l evels of total PAI-I and tPA/PAI-I complex were significantly higher in pat ients with DIG, pre-DIG, and TTP than in those with non-DIG. The plasma lev els of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor compl ex (PPIC), D-dimer, thrombomodulin (TM), total PAI-I, and tPA/PAI-I complex were significantly higher in patients with organ failure than in those wit hout organ failure. The plasma levels of total PAI-I and tPA/PAI-I complex were markedly increased in patients with acute leukemia. The plasma levels of total PAI-I, but not those of tPA/PAI-I complex, were significantly incr eased in patients with sepsis or with solid cancer. In all cases, total PAI -I or tPA/PAI-I complex was not significantly correlated with any hemostati c marker. Measurement of total PAI-I and tPA/PAI-I complex may be useful in the diagnosis of DIG.